Type I allergic reactions are mediated through the IgE high affinity receptor (FceRI). When a multivalent antigen is presented, a redistribution of the monomeric IgE FceRI receptor complexes cause the degranulation of mast cells and basophils, resulting in the subsequent release of factors responsible for type I allergic reactions. The FceRI receptor is a tetrameric complex, consisting of an a-chain, b-chain and a dimeric g-chain. While the a-chain is primarily involved with the binding of IgE, the signal is transferred through the g subunit, which contains the immunoreceptor tyrosine activation motifs (ITAM) critical for initiating receptor mediated signal transduction through the Syk and Lyn tyrosine kinases. The FceRI receptor is able to engage and disengage the IgE, providing a versatile model for studying the function of kinase coupled receptors.
Recognizes and is specific for FcεRI, γ-subunit.
Synthetic peptide corresponding to amino acids 80-86 of γ-subunit of Fc receptors.
Research Sub Category
Inflammation & Autoimmune Mechanisms
Milli-Mark Anti-FcεRI Antibody, γ subunit-FITC is an antibody against FcεRI for use in FC.
Inflammation & Immunology
Evaluated by flow cytometry using RBL cells.
10 kDa Calculated
Purified rabbit polyclonal IgG conjugated to FITC in PBS with 0.1% sodium azide and 15 mg/mL BSA.
Protein A purified
Storage and Stability
Maintain refrigerated at 2-8 °C protected from light in undiluted aliquots for up to 6 months from date of receipt.
Unconjugated antibody (Cat No. 06-727) has been shown to work on Human and Mouse.
MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.